key: cord-0714776-yxd5xb6w
authors: Lou, Yan; Zhao, Wenxiang; Wei, Haitao; Chu, Min; Chao, Ruihua; Yao, Hangping; Su, Junwei; Li, Yanan; Li, Xiulan; Cao, Yu; Feng, Yanyan; Wang, Ping; Xia, Yongyang; Shang, Yushuan; Li, Fengping; Ge, Pingju; Zhang, Xinglin; Gao, Wenjing; Song, Gaojie; Du, Bing; Liang, Tingbo; Qiu, Yunqing; Liu, Mingyao
title: Cross‐neutralization of RBD mutant strains of SARS‐CoV‐2 by convalescent patient derived antibodies
date: 2021-08-22
journal: Biotechnol J
DOI: 10.1002/biot.202100207
sha: fa37ff0808517cd62d3d1c7c4647208c2da76511
doc_id: 714776
cord_uid: yxd5xb6w

BACKGROUND: The emergence of COVID‐19 pandemic resulted in an urgent need for the development of therapeutic interventions. Of which, neutralizing antibodies play a crucial role in the prevention and resolution of viral infection. METHODS: We generated antibody libraries from 18 different COVID‐19 recovered patients and screened neutralizing antibodies to SARS‐CoV‐2 and its mutants. After 3 rounds of panning, 456 positive phage clones were obtained with high affinity to RBD (receptor binding domain). Clones were then reconstituted into whole human IgG for epitope binning assay and all 19 IgG were classified into 6 different epitope groups or Bins. RESULTS: Although all antibodies were found to bind RBD, the antibodies in Bin2 had superior inhibitory ability of the interaction between spike protein and angiotensin converting enzyme 2 receptor (ACE2). Most importantly, the antibodies from Bin2 showed stronger binding affinity or ability to mutant RBDs (N501Y, W463R, R408I, N354D, V367F, and N354D/D364Y) derived from different SARS‐CoV‐2 strains as well, suggesting the great potential of these antibodies in preventing infection of SARS‐CoV‐2 and its mutations. Furthermore, such neutralizing antibodies strongly restricted the binding of RBD to hACE2 overexpressed 293T cells. Consistently, these antibodies effectively neutralized wildtype and more transmissible mutant pseudovirus entry into hACE2 overexpressed 293T cells. In Vero‐E6 cells, one of these antibodies can even block the entry of live SARS‐CoV‐2 into cells at 12.5 nM. CONCLUSIONS: These results indicate that the neutralizing human antibodies from the patient‐derived antibody libraries have the potential to fight SARS‐CoV‐2 and its mutants in this global pandemic.

A newly emerged pathogen spreading worldwide named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now causing a pandemic and more than 172.84 million cases of infection and 3.71 million deaths worldwide. [1] This global pandemic threatens public health in a way more devastating than ever before. SARS-CoV-2 belongs to Sarbecovirus subgenus and shares substantial genetic and functional similarity with other pathogenic human betacoronaviruses, including

Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and

Middle East Respiratory Syndrome Coronavirus (MERS-CoV), [2, 3] whereas the unique pathogenesis and rapid international transmission of SARS-CoV-2 make it the most infectious and destructive coronavirus compared to SARS-CoV and MERS-CoV. [4] [5] [6] At present, several vaccines have been reported to be effective in phase III trials and have received emergency approval in numerous countries. [7] However, due to the mutations and complexity of SARS-CoV-2, the current global epidemic has not been completely restrained. Thus, therapeutic drugs that are effective and specific to SARS-CoV-2 and its mutants are still in urgent demand to put an end to the pandemic.

Similar to other coronaviruses, SARS-CoV-2 utilizes its envelope spike (S) glycoprotein to interact with a cellular receptor for entry into target cells. Angiotensin converting enzyme 2 (ACE2) has been identified as the main receptor for viral entry through triggering a cascade of cell membrane fusion events. [8] The spike glycoprotein is composed of two functional subunits, which is responsible for binding to the host cell receptor (S1 subunit) and fusion of the viral and cellular membranes (S2 subunit). The host range and cellular tropism of SARS-CoV-2 are determinated by the receptor-binding domain (RBD) within the S1 subunit. [9] Although the entry of SARS-CoV-2 into susceptible cells is a complex process and needs to be further explored, the receptorbinding and proteolytic processing of the S protein are regarded as the key events in promoting virus-cell fusion. While, an increasing amount of RBD mutants have been found under high positive selection pressure during the spread. Notably, new SARS-CoV-2 lineages carrying the mutation N501Y in the RBD of the spike protein which are more transmissible spread rapidly in the United Kingdom (UK). [10] The fact that such mutations increased the SARS-CoV-2 binding affinity to its host receptor ACE2 reveals a greater risk of more severe infections during a sustained pandemic of COVID-19. [11] Thus, common neutralization of interaction between ACE2 and RBD with different mutations could serve as a promising candidate for prophylactic and therapeutic interventions against SARS-CoV-2 infection. [12] During the last epidemic, SARS patients greatly benefited from convalescent serum collected from recovered subjects. [13] In a similar manner, the blood from COVID-19 patients who have recently become virus-free displayed serum neutralizing activities in a pseudotype entry assay. [14] However, the plasma neutralizing activity is low in most convalescent individuals. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested suggesting that humans are intrinsically have B cell clones that potently neutralize SARS-CoV-2. [15] Thus, it would be ideal to explore antibody cooperativity to develop a therapeutic antibody cocktail against SARS-CoV-2. [16] Different approaches can be developed to get full human antibodies against SARS-CoV, such as single B cell antibody cloning, [17] XenoMouse [18] and phage display, [19] [20] [21] of which phage display library facilitates the identification and development of specific affinity antibodies in a rapid and cost-effective manner. Several full human antibodies against the S1 domain have been generated and all of which can neutralize the virus in vitro and in vivo. [22] A panel of human neutralizing monoclonal antibodies targeting the SARS-CoV-2 RBD were selected from a phage display library constructed using peripheral circulatory lymphocytes collected from patients at the acute phase of the disease. [23] Furthermore, a naïve human semisynthetic phage library was also been used for identification of antibodies targeting the receptor-binding domain (RBD) of SARS-CoV-2. [24] In order 

As the source of therapeutic antibodies to COVID-19, the anti-SARS-CoV-2 B cells were noticeably enriched in COVID-19 convalescent patients. The PBMC from 18 different COVID-19 recovered patients were isolated to generate phage displayed scFv libraries for panning the neutralizing antibodies ( Figure 1a ). Prior to constructing the phage display library, we examined the binding ability of plasma from 18 recovered COVID-19 patients to SARS-CoV-2 RBD. It is observed that most convalescent patients were able to produce high titer of SARS-CoV-2 RBD-specific antibodies compared with healthy donors using enzyme-linked immunosorbent assay (ELISA) (Figure 1b) . Then, the phage display libraries from 18 patients were constructed and quality assessment of each library was undertaken by using RT-PCR clone counting and phage display ELISA. The correlation between the size of an antibody library and the likelihood of selecting for the desired antibodies is somewhat intuitive. As shown in Figure 1c , the size of primary libraries from patients ranged from 1.01 × 10 7 to 1.43 × 10 8 , which is consistent with other human immunized scFv libraries. [25] The total size of all libraries is larger than 10 9 . Ideally, the size of a library should (Figure 1d ,e). Taken together, our data revealed that the scFv library from COVID-19 recovered patients was constructed successfully.

Affinity selection of patient-derived antibody library was performed using solid-phase-bound RBD. In order to exclude the potential bias, the 18 libraries were selected to solid-phase-bound RBD individually. with highest affinity to RBD were reconstituted into whole human IgG for functional assay (Table S1 ) and S2 protein was used as a negative control to exclude non-specific binding (Figure 2b ). In order to characterize and group these IgG by the epitope binding regions generated against RBD, the "epitope binning" assay was performed on Octet systems. As shown in Figure 2c , 19 IgG can be divided into 6 different Bins. Of which, Bin1 and Bin2 are the biggest groups with 14 and 16 clones suggesting that these two epitopes on RBD are most important for recognizing by humoral immune system recognition. Therefore, engineering antibody that targets a specific functioning epitope on an RBD is more important than finding high-affinity, tight-binding mAb just to a non-functional site.

To further confirm the binding affinity of each IgG in Bin1 and Bin2, the RBD was bound in 96-well plates to complete an IgG binding assay. is only about 74% homologous to that of SARS-CoV. [26] Therefore, we used the IgG specific to SARS (CR3022) as a control to do the functional assay. We demonstrated that all the IgG (including HTS0422, HTS0433, HTS0446, HTS0483 and CR3022) bind to RBD specifically ( Figure 3e ). By contrast, only the four IgG (HTS0422, HTS0433, HTS0446 and HTS0483) from Bin2 could inhibit the interaction between RBD and hACE2 (Figure 3f ), suggesting that these antibodies may be bound to the key sites involved in the SARS-CoV-2 infection.

As an RNA virus, mutations in SARS-CoV-2 are not unusual, and can be found in various countries globally. Previous studies demonstrated that some mutations in RBD enhanced the binding affinity to the host cells. [27] Therefore, cross-neutralization against SARS-CoV-2 RBD mutations is essential for the development of an effective therapeutic antibody. In this study, six different SARS-CoV-2 RBD mutants (N501Y, R408I, W463R, N354D, V367F and N354D/D364Y) which were found in different regions all around the world were obtained from ACRO BIOSYSTEMS. As shown in Figure 4a , HTS0422, HTS0433 and HTS0446 bind with both wildtype and mutant (N501Y, W463R, N354D, V367F, both N354D and D364Y) RBD significantly. In addition, only HTS0483 binds with R408I, suggesting that R408I is essential for the binding of HTS0422, HTS0433 and HTS0446, and mutations at R408I abolished the binding of antibodies to the virus RBD, and HTS0483 may have broader cross-neutralization effect against SARS-CoV-2 RBD mutations. Accordingly, only HTS0483 inhibits the binding between ACE2 and all RBD mutants including W436R and R408I. While the other antibodies (HTS0422, HTS0433 and HTS0446) can only restrict the interaction between ACE2 and wildtype, N501Y, N354D, V367F or N354D/D364Y (Figure 4b) , implying that the mutations at W436R and R408I in RBD may cause the virus to escape from antibody blocking and, as a result, make the developing of broad vaccine become a considerable challenge. Meanwhile, it can also be found that even though all antibodies bind to N501Y significantly, the affinity of HTS0433 is much lower than the others as well as the inhibition of the binding between ACE2 and N501Y. What's more, although the CDR region is same between HTS0433 and HTS0446, there are three amino acids in the frame region of V L are different (DIV→AIR), suggesting that the frame region is also important in binding to N501Y mutation. This information will aid the affinity maturation of antibody to the more transmissible SARS-CoV-2 lineages with N501Y mutation.

To explore the potential of the top four IgG (HTS0422, HTS0433, HTS0446 and HTS0483) as therapeutic drugs, we tested whether these IgG can block the binding of RBD to hACE2 expressed cells by flow cytometry analysis. We found that these top four IgG from Bin2 could restrict the binding of RBD to hACE2-293T cells but not CR3022, which bind to both SARS and SARS-CoV-2 RBD (Figure 5a ). Furthermore, we determined the neutralization ability of these four IgG using a SARS-CoV-2 S pseudotyped lentiviral particle. Consistent with ELISA As shown in Figure S1A , although HTS0422, HTS0433 and HTS0446

bind with RBD of SARS-CoV-2, SARS-CoV and MERS-CoV, HTS0483

only specifically bind to the RBD of SARS-CoV-2, suggesting that the binding site of HTS0483 is unique to SARS-CoV-2.

Although different approaches have been taken to develop therapeutic antibodies for infectious diseases, phage display library persists as the common method for the generation of recombinant antibodies against various targets for biomedical applications and research. [28] Up till now, 9 fully human therapeutic antibodies discovered via phage display were approved by the Food and Drug Administration (FDA). [29] In this study, we constructed phage displayed human scFv libraries from Similar to other coronaviruses, SARS-CoV-2 uses the homotrimeric spike glycoprotein (comprising a S1 subunit and S2 subunit in each spike monomer) on the envelope to bind to their cellular receptors ACE2. The previous study demonstrated that the binding of SARS-CoV and SARS-CoV-2 spike glycoproteins with ACE2 induces the dissociation of S1 with ACE2, prompting the S2 to transit from a metastable pre-fusion to a more-stable post-fusion state that is essential for membrane fusion. [9, 30, 31] Furthermore, in vitro measurements indicate that the RBD is a key functional component within the S1 subunit and is responsible for binding of SARS-CoV-2 by ACE2. [32] Although Although more than 400 positive clones were identified to bind with RBD by ELISA assay, only a part of them could block the interaction between RBD and ACE2 significantly, which is consistent with previous data that not all antibodies against RBD have the neutralizing ability to interact with ACE2. [33] Therefore, we sorted panel of selected antibodies according to epitope specificities by epitope binning assay. Bin2 had similar binding affinity to RBD. However, the neutralizing or blocking ability of antibodies in Bin2 was much better than in Bin1, suggesting that the epitope of Bin2 is essential for ACE2 binding. Next, we checked the sequence of each antibody and found that there were 12 antibodies could be found with sequence pattern **GMDV in CDR3 of V H among all 19 antibodies including HTS0483 (Table S1) These data suggested that the W436R and R408I are essential for the bind of HTS0422, HTS0433 and HTS0446 ( Figure S7b) . Accordingly, the R408I mutation within RBD exhibiting low antigenicity which will eliminate the neutralization to SARS-CoV-2 by those antibodies. [34] Although the RBD domain is important for the viral infection, it seems that the lack of linear epitopes makes it hard to get neutralizing antibodies. Furthermore, the linear-epitope-specific antibodies which immunized mice failed to neutralize the authentic virus implied that conformational epitopes are crucial for developing neutralizing antibodies. [35] Therefore, if we can make some point mutation in RBD to explore the conformational epitopes in Bin2, the actual residues that mediate the interaction between RBD and ACE2 will be discovered.

So far, 36 nonsynonymous mutations were identified in RBD of the spike protein with a low prevalence (<1%) across all genomes. [36] And some of them such as N501Y in the United Kingdom has been proven to increase the infectivity and became the dominant lineage.

In addition, the S protein is also important for antigen cognition.

Thus, the variation of S protein may change the antigen of virus and influence the vaccine immune efficiency. It has been demonstrated that N439K mutation which has been found in more than 30 countries confer resistance against several neutralizing monoclonal antibodies, including one authorized for emergency use by the FDA. [37] Therefore, Some evidences have shown that the convalescent serum from a patient with a SARS-CoV infection and horse anti-SARS-CoV serum could cross-neutralize the infection of SARS-CoV-2, which implies that the structures of RBDs in SARS-CoV-2 and SARS-CoV are similar. [3, 8] While most antibodies targeting SARS-CoV have little cross-binding and neutralization activity against spike protein or RBD of SARS-CoV-2 (except SARS-CoV antibody CR3022 which binds to the SARS-CoV-2 RBD with a KD of 6.2 nM). [38, 39] In this study, we demonstrated that the binding affinity of CR3022 is lower than 4 antibodies from Bin2. Furthermore, the neutralization activity of CR3022 against RBD of SARS-CoV-2 to ACE2 is vanished when compared to our antibodies, implying that the binding motif of SARS-CoV may be different from SARS-CoV-2. In addition, the pseudovirus entry and authentic virus infection of Vero-E6 are both inhibited significantly by these antibodies. Then, the RBD sequence between SARS-CoV-2 and SARS-CoV was compared and we found that the W436R and R408I are same in both, which suggested that the binding to these sites couldn't distinguish SARS-CoV-2 and SARS-CoV. [40] Most importantly, the specific binding of HTS0483 to SARS-CoV-2 makes it possible to find a novel motif only displayed on SARS-CoV-2 but not SARS-CoV or MERS-CoV. Thus, the HTS0483 could be used as a tool to explore the unique properties of SARS-CoV-2.

In summary, patient-derived antibody libraries were constructed for developing therapeutic antibodies against COVID-19 pandemic and the neutralizing monoclonal antibodies not only have the potential for clinical application, but will also benefit the mechanism in exploring SARS-CoV-2 entry to host cells.

The study enrolled a total of 18 COVID-19 patients (#202000004771, followed by the addition of HRP-conjugated antibody against human IgG and subsequent incubation for 1 h at room temperature. Wells were washed three times and then TMB was added. Following 20 min of incubation at room temperature, the reaction was stopped and the color reaction was read at 450 nm on an ELISA reader.

Total RNA was prepared from PBMCs of 18 convalescent COVID-19 patients followed by cDNA synthesis with a reverse transcription kit (RR036B, Takara) according to the manufacturer's instructions. The genes of variable regions of heavy chain and light chain (V H and V L ) were amplified separately with the primers listed in Table S2 and then were further cloned into the phage-display vector pCANTAB-5E (GE Healthcare) with SfiI/XhoI or NheI/NotI digestion. The recombinant DNAs were transformed into Escherichia coli (E. coli) TG1 by electroporation. The transformants were plated on dishes containing 2-YT agar (1.6% tryptone, 1% yeast extract, 0.5% NaCl, 1.5% bacteriological agar) with 100 µg ml -1 ampicillin and 2% glucose. Following overnight incubation, all the colonies were scraped off the dishes, counted and finally stored at −80 • C as a primary library. Ninety six single colonies from the primary library were randomly picked out, then the scFv gene were amplified with polymerase chain reaction (PCR) to detect the insert rate with electrophoresis and these colonies were also send out for DNA sequencing to calculate the correct rate of insert genes.

Subsequently, the same phages TG1 transformants were superinfected with M13KO7 helper phage in a MOI (multiplicity of infection) ratio of 5:1, and scFv-phages produced in overnight culture were purified with 20% PEG8000 and 2.5 M NaCl. ScFv molecules displayed by rescued phages were detected via the Myc tag in the scFv-pIII fusion protein using ELISA.

The 96-well plate were coated with RBD in PBS, blocked for 2 h with 

In order to obtain a large number of antibodies, the genes for V H of selected scFv were cloned into pTT5-hIgG1 vector (containing the DNA coding sequence for IgG1-C H ) while V L genes were cloned into pTT5-hKappa vector separately. The recombinant plasmids were then co-transfected into 293F cells together with PEI. After 5 days' culture, the antibodies in supernatant were collected and purified by protein A resin for whole IgG. At last, the antibodies were dialyzed to PBS for 16 h and filtration sterilized with 0.22 µm filter for long term preservation.

Antibody binding ELISA with RBD or RBD mutants 96-well plates were coated with RBD or other RBD mutants in PBS, blocked for 2 h with 2% BSA, and incubated with a serial dilution of purified whole IgG antibodies. After three washes with PBST, the bound antibodies were detected by HRP-conjugated anti-human Fc antibody followed by incubation with TMD before the color reaction was measured.

To detect the binding of antibodies to the RBD of SARS-CoV-2, SARS-CoV and MERS-CoV, 96-well plates were coated with SARS and MERS RBD in PBS, blocked 2 h with 2% BSA, and incubated with a serial dilution of purified whole IgG antibodies. After three washes with PBST, the bound antibodies were detected by HRP-conjugated antihuman Fc antibody followed by incubation with TMD and the color reaction was measured.

Competitive inhibition ELISA assay RBD or RBD mutants were incubated for 1 h at room temperature with a serial dilution of purified whole IgG antibodies. The above mixture was subjected to 96-well plate coated with ACE2 and incubated for another 1 h at 4 • C. HRP-conjugated anti-mouse Fc was added as secondary antibody. The following procedures were the same as described in ELISA.

The human ACE2 gene (NM_021804.1) was synthesized and cloned 

Production of HIV pseudotyped with SARS-CoV-2 spike (wildtype and mutants N501Y, W436R, R408I, N354D, V367F and N354D/D364Y were all purchased from Acro biosystems) was performed using the standard lentivirus production method. Briefly, 293T cells were transfected with psPAX2 and vectors encoding SARS-CoV-2 spike protein as well as a core plasmid expressing RFP. After 48 h post-infection, RFP/SARS-CoV-2 spike pseudoviruses were packaged and collected from the culture supernatant. All the sequence of RBD and S protein used in this study was listed in the Table S3.

Neutralization activity of mAbs against pseudovirus RFP/SARS-CoV-2 spike pseudovirus system was used as an infection model to evaluate the neutralization activity of antibodies. First, the RFP/SARS-CoV-2 spike pseudoviruses were pre-incubated with a serial dilution of purified whole IgG antibodies. Then, 293T-ACE2 cells were infected by the RFP/SARS-CoV-2 spike pseudovirus with or without antibodies. After 2 h incubation at 37 • C, the medium was refreshed with DMEM containing 10% FBS and continuously cultured for another 72 h. The infected 293T-ACE2 cells were observed under microscope and the neutralizing IC 50 was calculated after FACS detection.

Neutralization activity of mAbs against live SARS-CoV-2 SARS-CoV-2 obtained from a sputum sample was amplified in Vero-E6 to make working stocks of the virus. To analyze the mAb neutralizing activities, two-fold serial dilutions of mAbs were added to the same volume of 100 TCID 50 of SARS-CoV-2 and incubated for 1 h at 37 • C.

The mixture was added to a monolayer of Vero-E6 cells in a 96-well plate and incubated at 37 • C. Cytopathic effects (CPE) were observed and recorded from day 4 to day 6. For immunofluorescence (IF) analysis, Vero-E6 cells were transfected and fixed on day 6 post-transfection in 80% acetone for 10 min at room temperature. Cells were immunolabeled for 1.5 h at room temperature with the rabbit anti SARS-CoV-2 spike antibody, washed three times with PBS, and followed by the addition of Alexa Fluor 488-conjugated goat anti-rabbit IgG antibody. Wells were washed three times and then DAPI was added. Following 30 min of incubation at room temperature, the reaction was reading in fluorescent microscopy. 

The authors declare no conflict of interest. 

Multi-epitope vaccine design using an immunoinformatic approach for SARS-CoV-2. Pathogens

Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The lancet

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

Mutations strengthened SARS-CoV-2 infectivity

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Use of convalescent plasma therapy in SARS patients in Hong Kong

Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse

Perspectives on therapeutic neutralizing antibodies against the novel Coronavirus SARS-CoV-2

Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals

By-passing immunization. Human antibodies from V-gene libraries displayed on phage

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

Identification of an anti-SARS-CoV-2 receptor-binding domain-directed human monoclonal antibody from a naive semisynthetic library

Generation of a stable anti-human CD44v6 scFv and analysis of its cancertargeting ability in vitro

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections

Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics

Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy

Designing human antibodies by phage display

Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Mutations in SARS-CoV-2 leading to antigenic variations in spike protein: A challenge in vaccine development

Isolating SARS-CoV-2 strains from countries in the same meridian: Genome evolutionary analysis

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Cross-neutralization of RBD mutant strains of SARS-CoV-2 by convalescent patient derived antibodies

Pingju Ge, Xinglin Zhang and Wenjing Gao performed the experiments.Bing Du, Wenxiang Zhao, Gaojie Song, Ruihua Chao, and Mingyao Liu analyzed the data. Bing Du and Ruihua Chao wrote the manuscript.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Bing Du https://orcid.org/0000-0002-5402-6527